Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TuHURA Biosciences, Inc. (HURA : NSDQ)

• Company Description    TuHURA Biosciences Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA Biosciences Inc., formerly known as Kintara Therapeutics Inc., is based in SAN DIEGO. Number of Employees: 19

• Price / Volume Information    Yesterday's Closing Price: $2.50 Daily Weekly Monthly 20 Day Moving Average: 271,901 shares Shares Outstanding: 50.05 (millions) Market Capitalization: $125.12 (millions) Beta: -0.10 52 Week High: $7.93 52 Week Low: $1.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.42% -11.01% 12 Week -7.41% -15.89% Year To Date -38.88% -43.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10500 UNIVERSITY CENTER DR. SUITE 110 - TAMPA,FL 33612 USA ph: 813-875-6600 fax: 604-608-5685 tuhurabio@jtcir.com https://tuhurabio.com

• General Corporate Information    Officers James A. Bianco - Chief Executive Officer; President and Director James Manuso - Chairman of the Board Dan Dearborn - Chief Financial Officer James Manuso - Director Alan List - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 898920103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 50.05 Most Recent Split Date: 10.00 (0.03:1) Beta: -0.10 Market Capitalization: $125.12 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.66 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.70 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -40.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -248.79 03/31/25 - -497.66 12/31/24 - -1,529.15 ROA 06/30/25 - -150.83 03/31/25 - -208.29 12/31/24 - -198.70 Current Ratio 06/30/25 - 0.83 03/31/25 - 3.00 12/31/24 - 3.68 Quick Ratio 06/30/25 - 0.83 03/31/25 - 3.00 12/31/24 - 3.68 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.44 03/31/25 - 0.22 12/31/24 - 0.34 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©